1. Biotherapeutics

3. Introduction

4. Program Outline

5. Immunogenicity of Biologics in Chronic Inflammatory Diseases

6. Complex Nature of ADAs

7. Neutralizing and Non-Neutralizing Antibodies

8. Neutralizing and Non-Neutralizing Antibodies (Cont.)

9. Impact of ADAs

10. Factors Associated With Immunogenicity

11. MTX Reduces Immunogenicity in a Dose- Dependent Manner

12. Biologic Agent Monitoring in Daily Practice

13. Model: ADA Development and Decreased Biologic Serum Concentration

14. Biologic Agent Monitoring in Daily Practice

15. Measurement of Biologic Drug Serum Trough Concentration

16. Response to Targeted Treatment in RA

17. Potential Predictors of Response to Anti-TNF Treatment

18. Considerations for Patients With Loss of Response to Biologic Therapy

19. Reduction of Overexposure in Patients With RA and High Serum ADA Concentrations

20. RA Treatment Based on Antibody Responses?

21. Serum Drug Levels of Biologic Agents in the Management of RA: A Systematic Review

22. Potential Predictors of Response to Anti-TNF Treatment

23. EULAR Recommendations for the Management of RA With csDMARDs and bDMARDs

24. MTX Use in Patients With PsA or axSpA

25. Biosimilars and Their Reference Agents Are Interchangeable

26. The Data Requirements for Biosimilar Approval Are Comprehensive

27. NOR-SWITCH: Switching From Originator Infliximab to Biosimilar CT-P13

28. RCTs of Switching From Originator Infliximab to Biosimilar Infliximab in RA

29. Recommendations Regarding the Use of Biosimilars in Patients With RA

30. Use of Biosimilars: Discussion Points With Patients

31. Biosimilar Switching: Evidence From Arthritis Studies

32. Abbreviations

33. Abbreviations (cont)